- Home
- MIRA vs CYTH Comparison
MIRA vs CYTH Comparison
Compare MIRA & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CYTH
- Stock Information
- Founded
- MIRA 2020
- CYTH 1990
- Country
- MIRA United States
- CYTH United States
- Employees
- MIRA N/A
- CYTH N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- CYTH Health Care
- Exchange
- MIRA Nasdaq
- CYTH Nasdaq
- Market Cap
- MIRA 17.1M
- CYTH 20.4M
- IPO Year
- MIRA 2023
- CYTH N/A
- Fundamental
- Price
- MIRA $1.47
- CYTH $0.71
- Analyst Decision
- MIRA Strong Buy
- CYTH Buy
- Analyst Count
- MIRA 2
- CYTH 3
- Target Price
- MIRA $14.00
- CYTH $0.95
- AVG Volume (30 Days)
- MIRA 3.6M
- CYTH 23.7K
- Earning Date
- MIRA 11-12-2024
- CYTH 11-14-2024
- Dividend Yield
- MIRA N/A
- CYTH N/A
- EPS Growth
- MIRA N/A
- CYTH N/A
- EPS
- MIRA N/A
- CYTH N/A
- Revenue
- MIRA N/A
- CYTH $1,132,430.00
- Revenue This Year
- MIRA N/A
- CYTH N/A
- Revenue Next Year
- MIRA N/A
- CYTH $24.49
- P/E Ratio
- MIRA N/A
- CYTH N/A
- Revenue Growth
- MIRA N/A
- CYTH 24.65
- 52 Week Low
- MIRA $0.51
- CYTH $0.59
- 52 Week High
- MIRA $6.40
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- MIRA 48.43
- CYTH 46.91
- Support Level
- MIRA $1.65
- CYTH $0.70
- Resistance Level
- MIRA $1.75
- CYTH $0.77
- Average True Range (ATR)
- MIRA 0.33
- CYTH 0.04
- MACD
- MIRA -0.03
- CYTH -0.00
- Stochastic Oscillator
- MIRA 13.01
- CYTH 28.38
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.